Emicizumab

Roche's next-generation bispecific antibody NXT007 achieved no treated bleeds in the highest dose cohorts of a phase I/II trial involving 30 hemophilia A patients without factor VIII inhibitors.

Novo Nordisk's phase 3b FRONTIER5 trial demonstrated that patients with hemophilia A can safely switch directly from emicizumab to investigational Mim8 prophylaxis without requiring a washout period.

Chugai Pharmaceutical, the Japanese biotech behind Eli Lilly's oral obesity drug orforglipron, plans to combine it with its anti-muscle wasting drug GYM329 to create a new standard of care for weight loss patients.

Novo Nordisk will present new phase 3 trial data for two investigational hemophilia treatments, Mim8 (denecimig) and concizumab, at the International Society on Thrombosis and Haemostasis Congress from June 21-25, 2025.

• The Federal Circuit has affirmed the Patent Trial and Appeal Board's decision invalidating two patents covering experimental gene therapy for hemophilia treatment, handing Pfizer a significant legal victory. • The invalidated patents were related to novel gene therapy approaches for hemophilia, highlighting the competitive landscape in developing advanced treatments for this rare bleeding disorder. • This ruling represents an important precedent in the gene therapy intellectual property space, potentially impacting future development and commercialization of similar therapeutic approaches.